newsfilter
← Latest News
PR Newswire·

Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals

- Alar's Lead Asset ALA-1000 Potentially is the First Three-Month LAI Treatment for OUD - RICHMOND, Va., Oct. 11, 2023 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV), a leading addiction treatment company, today